Related Experiment Videos
Autologous bone marrow transplantation for leukemia
1Department of Medicine, Medical University of South Carolina, Charleston 29425.
Seminars in Oncology
|October 1, 1993
Summary
Autologous bone marrow transplants offer curative potential for leukemia, but relapse remains a challenge. Research focuses on improving purging techniques and conditioning regimens to enhance leukemia-free survival.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Autologous bone marrow transplantation (ABMT) was developed for leukemia patients lacking histocompatible donors.
- A key challenge is preventing leukemia relapse due to reinfusion of malignant cells in harvested marrow.
Purpose of the Study:
- To evaluate the efficacy and challenges of ABMT for leukemia.
- To explore the role of ex vivo antileukemic treatment (purging) in improving outcomes.
Main Methods:
- Analysis of clinical trials involving ABMT for acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL).
- Investigation of purging techniques for ex vivo leukemia cell removal.
- Comparison of outcomes between autologous and allogeneic transplants.
Main Results:
- ABMT has demonstrated curative potential for selected AML and ALL patients.
- Purging may increase leukemia-free survival in high-risk patients, though its benefit is debated.
- Procedure-related mortality is lower for ABMT than allogeneic transplants, but relapse rates are higher, leading to similar long-term survival.
Conclusions:
- ABMT is a viable option, particularly for older patients or those without matched donors.
- Leukemia relapse remains a significant limitation, especially in ALL.
- Further research is needed to optimize conditioning regimens, purging strategies, and immune manipulation for ABMT.